Compugen Ltd. (USA)  

(Public, NASDAQ:CGEN)   Watch this stock  
Find more results for CGEN
6.29
+0.06 (0.96%)
Jul 30 - Close
NASDAQ real-time data - Disclaimer
Currency in USD
Range 6.07 - 6.32
52 week 5.71 - 10.02
Open 6.21
Vol / Avg. 92,428.00/136,634.00
Mkt cap 325.57M
P/E     -
Div/yield     -
EPS -0.31
Shares 50.25M
Beta 0.99
Inst. own 13%
Aug 7, 2015
Compugen Ltd Annual Shareholders Meeting (Estimated) - 3:00AM EDT - Add to calendar
Aug 4, 2015
Q2 2015 Compugen Ltd Earnings Call - 10:00AM EDT - Add to calendar
Aug 4, 2015
Q2 2015 Compugen Ltd Earnings Release Add to calendar
Jul 22, 2015
Compugen Ltd Annual Shareholders Meeting
Jun 8, 2015
Compugen Ltd Investor and Analyst Meeting
Jun 4, 2015
Compugen Ltd at Jefferies Global Healthcare Conference
May 5, 2015
Q1 2015 Compugen Ltd Earnings Call
May 5, 2015
Q1 2015 Compugen Ltd Earnings Release
More events from DailyFinance »    

Key stats and ratios

Q1 (Mar '15) 2014
Net profit margin -1197.47% -89.71%
Operating margin -1232.36% -99.76%
EBITD margin - -94.44%
Return on average assets -22.05% -12.92%
Return on average equity -23.80% -16.08%
Employees 83 -
CDP Score - -

Address

72 Pinchas Rosen Street
TEL AVIV-YAFO, 6951294
Israel
+972-3-7658585 (Phone)
+972-3-7658555 (Fax)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money

Description

Compugen Ltd. is a drug discovery company. The Company is focused on the discovery and development of monoclonal antibodies (mAbs) and therapeutic proteins in the fields of oncology and immunology. Its business model includes entering into collaborations covering the further development and commercialization of product candidates at various stages from its pipeline program and various forms of research and discovery agreements. It has established the pipeline program, consisting of targets and product candidates for applications in oncology and immunology, based on immune checkpoint regulator candidates. Potential therapeutic proteins for immunology include CGEN-15001, CGEN-15021, CGEN-15091, CGEN-15031 and CGEN-15051. Its infrastructure platforms include LEADS, MED and NexGen. Its individual discovery capabilities are mAb Target Discovery, Protein Family Members Discovery Platform and Antibody-Drug Conjugate Cancer Therapy Discovery Platform, among others.

Officers and directors

Martin S. Gerstel Chairman of the Board
Age: 73
Bio & Compensation  - Reuters
Anat Cohen-Dayag Ph.D. President, Chief Executive Officer, Director
Age: 48
Bio & Compensation  - Reuters
Ari Krashin Chief Financial Officer
Age: 42
Bio & Compensation  - Reuters
Zurit Levine Ph.D. Vice President - Research and Discovery
Age: 47
Bio & Compensation  - Reuters
John Hunter Vice President - Antibody Research & Development
Age: 52
Bio & Compensation  - Reuters
Dov Hershberg Director
Age: 75
Bio & Compensation  - Reuters
Yair Aharonowitz Ph.D. Independent External Director
Age: 74
Bio & Compensation  - Reuters
Ruth Arnon Independent Director
Age: 80
Bio & Compensation  - Reuters
Arie Ovadia Ph.D Independent External Director
Age: 66
Bio & Compensation  - Reuters
Joshua Shemer M.D. Independent External Director
Bio & Compensation  - Reuters